formononetin could increase soluble-appα secretion by up-regulating adam10 level

1
ORAL PRESENTATION Open Access Formononetin could increase soluble-APPa secretion by up-regulating ADAM10 level Ting Zhou, Miao Shun, Liang Zhou, Huan Yang, Kaiyin Zhong, Ximeng Zhang, Hui Zhang, Dongsheng Fan, Dehua Chui * From 2011 International Conference on Molecular Neurodegeneration Shanghai, China. 22-24 September 2011 Background Formononetin, which is used as neuroprotective medicine, was reported to have benefits for Alzheimers disease (AD). However, little is known on how Formononetin exerts these beneficial effects. In this study, we investigated the molecular mechanisms through which Formononetin increased soluble-APPa (sAPPa) secretion and thus was neuroprotective in human-APP Swedish mutation cell cul- tures (N2a-APP cell). Method and results By using N2a-APP cell cultures combined with hypoxia treatment, we confirmed that chronic treatment with Formononetin could have neuroprotective effects, which was followed by reduced and increased Caspase3 activity and cell viability. Strikingly, our data revealed that the Caspase3-blocking effect of Formononetin was largely mediated by stimulation of a-secretase cleavage of APP, resulting in increased secretion of its soluble form, sAPPa. Moreover, the protective effect of Formononetin was totally inhibited by TAPI-2, an a-secretase complex inhibitor, suggesting the role of the sAPPa pathway in the neuroprotective response to Formononetin. Further- more, we also revealed that the stimulation effect of Formononetin on a-secretase activity was mainly a result of up-regulating ADAM10 expression at the tran- scriptional level. Conclusion Altogether, our study provides novel insights into how Formononetin mediated stimulation of the ADAM10- sAPPa pathway and resulting neuronal protective effect. Acknowledgment We thank Dr. Sangram S. Sisodia (University of Chicago, Chicago) for providing Mouse N2a neuroblastoma cells stably expressing PS1wt and APPsw. This work was supported by the National Natural Science Foundation of China (NSFC; Grants No.30973145), Doctoral Fund of Ministry of Education (20090001110058) and the National High Technology Research and Development Program of China (973 Program, No. 2012CB911004). Published: 7 February 2012 doi:10.1186/1750-1326-7-S1-O10 Cite this article as: Zhou et al.: Formononetin could increase soluble- APPa secretion by up-regulating ADAM10 level. Molecular Neurodegeneration 2012 7(Suppl 1):O10. Submit your next manuscript to BioMed Central and take full advantage of: Convenient online submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit * Correspondence: [email protected] Peking University Neuroscience Research Institute, Dep. of Neurology, Peking University Third Hospital, Beijing 100191, China Zhou et al. Molecular Neurodegeneration 2012, 7(Suppl 1):O10 http://www.molecularneurodegeneration.com/content/7/S1/O10 © 2012 Zhou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Upload: ting-zhou

Post on 06-Jul-2016

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Formononetin could increase soluble-APPα secretion by up-regulating ADAM10 level

ORAL PRESENTATION Open Access

Formononetin could increase soluble-APPasecretion by up-regulating ADAM10 levelTing Zhou, Miao Shun, Liang Zhou, Huan Yang, Kaiyin Zhong, Ximeng Zhang, Hui Zhang, Dongsheng Fan,Dehua Chui*

From 2011 International Conference on Molecular NeurodegenerationShanghai, China. 22-24 September 2011

BackgroundFormononetin, which is used as neuroprotective medicine,was reported to have benefits for Alzheimer’s disease(AD). However, little is known on how Formononetinexerts these beneficial effects. In this study, we investigatedthe molecular mechanisms through which Formononetinincreased soluble-APPa (sAPPa) secretion and thus wasneuroprotective in human-APP Swedish mutation cell cul-tures (N2a-APP cell).

Method and resultsBy using N2a-APP cell cultures combined with hypoxiatreatment, we confirmed that chronic treatment withFormononetin could have neuroprotective effects, whichwas followed by reduced and increased Caspase3 activityand cell viability. Strikingly, our data revealed that theCaspase3-blocking effect of Formononetin was largelymediated by stimulation of a-secretase cleavage of APP,resulting in increased secretion of its soluble form,sAPPa. Moreover, the protective effect of Formononetinwas totally inhibited by TAPI-2, an a-secretase complexinhibitor, suggesting the role of the sAPPa pathway inthe neuroprotective response to Formononetin. Further-more, we also revealed that the stimulation effect ofFormononetin on a-secretase activity was mainly aresult of up-regulating ADAM10 expression at the tran-scriptional level.

ConclusionAltogether, our study provides novel insights into howFormononetin mediated stimulation of the ADAM10-sAPPa pathway and resulting neuronal protective effect.

AcknowledgmentWe thank Dr. Sangram S. Sisodia (University of Chicago, Chicago) forproviding Mouse N2a neuroblastoma cells stably expressing PS1wt andAPPsw. This work was supported by the National Natural ScienceFoundation of China (NSFC; Grants No.30973145), Doctoral Fund of Ministryof Education (20090001110058) and the National High Technology Researchand Development Program of China (973 Program, No. 2012CB911004).

Published: 7 February 2012

doi:10.1186/1750-1326-7-S1-O10Cite this article as: Zhou et al.: Formononetin could increase soluble-APPa secretion by up-regulating ADAM10 level. MolecularNeurodegeneration 2012 7(Suppl 1):O10.

Submit your next manuscript to BioMed Centraland take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

* Correspondence: [email protected] University Neuroscience Research Institute, Dep. of Neurology, PekingUniversity Third Hospital, Beijing 100191, China

Zhou et al. Molecular Neurodegeneration 2012, 7(Suppl 1):O10http://www.molecularneurodegeneration.com/content/7/S1/O10

© 2012 Zhou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.